By Amechi Idumuebor (AGENDAWATCHDOG) – Human trials for Moderna’s COVID-19 vaccine would enter Phase 3, its final stage from July 27 until October 27, after promising early results were published in a journal. 30,000 volunteers would be recruited in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half will receive a placebo.
The exercise is geared towards understanding whether the vaccine can prevent COVID-19, or, to see whether it can prevent the infection from progressing towards symptoms, if people ultimately get infected. The vaccine would still be considered a success if it stops severe cases of COVID-19, even if people develop symptoms.
Moderna is in pole position, ahead of Chinese, Russian and pharmaceutical companies from other countries, in the global race to find a COVID-19 vaccine, which has infected approximately 13.2 million people and killed 570,000.